Status:
COMPLETED
Clinical Translation of a Novel FAPI Dimer [68Ga]Ga-LNC1013
Lead Sponsor:
Xiangya Hospital of Central South University
Conditions:
Gastrointestinal Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Fibroblast activation protein (FAP) emerges as a highly promising target for cancer diagnostic imaging and targeted radionuclide therapy. To exploit the therapeutic potential of current FAP inhibitors...
Detailed Description
Three new FAPI dimers were synthesized by linking two quinoline-based FAPIs with different spacers. The in vitro binding affinity and preclinical small animal PET imaging of the compounds were compare...
Eligibility Criteria
Inclusion
- Histologically and/or clinically confirmed and/or suspicious of gastrointestinal cancer.
- Signed informed consent.
Exclusion
- pregnancy;
- breastfeeding;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
July 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 25 2022
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT06159049
Start Date
July 21 2022
End Date
November 25 2022
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jian Li
Changsha, Hunan, China